Eli Lilly and Co (LLY)
770.00
-1.12
(-0.15%)
USD |
NYSE |
May 17, 16:00
770.99
+0.99
(+0.13%)
After-Hours: 20:00
Eli Lilly Cash and Short Term Investments (Annual): 2.928B for Dec. 31, 2023
Cash and Short Term Investments (Annual) Chart
Historical Cash and Short Term Investments (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.928B |
| December 31, 2022 | 2.212B |
| December 31, 2021 | 3.909B |
| December 31, 2020 | 3.681B |
| December 31, 2019 | 2.438B |
| December 31, 2018 | 7.409B |
| December 31, 2017 | 8.034B |
| December 31, 2016 | 6.039B |
| December 31, 2015 | 4.452B |
| December 31, 2014 | 4.827B |
| December 31, 2013 | 5.397B |
| December 31, 2012 | 5.684B |
| December 31, 2011 | 6.897B |
| December 31, 2010 | 6.727B |
| December 31, 2009 | 4.498B |
| December 31, 2008 | 5.926B |
| December 31, 2007 | 4.831B |
| December 31, 2006 | 3.891B |
| December 31, 2005 | 5.038B |
| December 31, 2004 | 7.464B |
| Date | Value |
|---|---|
| December 31, 2003 | 3.713B |
| December 31, 2002 | 3.655B |
| December 31, 2001 | 3.731B |
| December 31, 2000 | 4.618B |
| December 31, 1999 | 3.836B |
| December 31, 1998 | 1.496B |
| December 31, 1997 | 1.948B |
| December 31, 1996 | 813.70M |
| December 31, 1995 | 999.50M |
| December 31, 1994 | 536.90M |
| December 31, 1993 | 539.60M |
| December 31, 1992 | 432.40M |
| December 31, 1991 | 479.20M |
| December 31, 1990 | 350.20M |
| December 31, 1989 | 323.00M |
| December 31, 1988 | 761.50M |
| December 31, 1987 | 1.031B |
| December 31, 1986 | 486.00M |
| December 31, 1985 | 406.10M |
| December 31, 1984 | 445.30M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Annual) Range, Past 5 Years
2.212B
Minimum
2022
3.909B
Maximum
2021
3.034B
Average
2.928B
Median
2023
Cash and Short Term Investments (Annual) Benchmarks
| Amgen Inc | 10.94B |
| Biogen Inc | 1.050B |
| Johnson & Johnson | 22.93B |
| Vertex Pharmaceuticals Inc | 11.22B |
| Viking Therapeutics Inc | 362.08M |